Does Rallies show 13F holders for KPTI?

Yes. Rallies tracks hedge fund and 13F ownership data for KPTI, including fund names, share counts, latest tracked quarter, and position changes when available.

Is KPTI research on Rallies investment advice?

No. Rallies provides research, data, and educational context for KPTI. It does not provide personalized investment advice.

KPTI (Karyopharm Therapeutics Inc.) Stock Analysis - Hedge Fund Holdings

Karyopharm Therapeutics Inc. (KPTI) is a publicly traded Healthcare sector company. As of May 21, 2026, KPTI trades at $7.85 with a market cap of $161.81M and a P/E ratio of -0.48. KPTI moved +6.69% today. Year to date, KPTI is +7.84%; over the trailing twelve months it is +54.80%. Its 52-week range spans $3.51 to $16.95. Analyst consensus is strong buy with an average price target of $15.83. Rallies surfaces KPTI's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns KPTI stock?

Hedge funds tracked by Rallies that own KPTI include Davidson Kempner and Panagora Asset. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Karyopharm Therapeutics Inc..

KPTI Key Metrics

Key financial metrics for KPTI
Metric	Value
Price	$7.85
Market Cap	$161.81M
P/E Ratio	-0.48
EPS	$-16.16
Dividend Yield	0.00%
52-Week High	$16.95
52-Week Low	$3.51
Volume	222
Avg Volume	0
Revenue (TTM)	$151.12M
Net Income	$-194.97M
Gross Margin	0.00%

Top Hedge Funds Holding KPTI

Davidson Kempner holds 300.00K shares of KPTI, changed -3.23% as of Mar 31, 2026.
Panagora Asset holds 229.92K shares of KPTI, changed +1.09% as of Mar 31, 2024.

Latest KPTI News

Karyopharm Posts Q1 Revenue Growth, Cuts Loss to $22.4M, Completes EC042 Enrollment — May 15, 2026
Karyopharm Therapeutics Beats Q1 Estimates with $35.07M Revenue, -$1.02 EPS — May 14, 2026
Karyopharm Narrows Q4 Loss to $2.23 Per Share, Beats Revenue Forecasts — Feb 12, 2026

Recent KPTI Insider Trades

Poulton Stuart sold 403 (~$3.83K) on May 14, 2026.
Rangwala Reshma sold 408 (~$3.88K) on May 14, 2026.
Cheng Sohanya Roshan sold 324 (~$3.08K) on May 14, 2026.

KPTI Analyst Consensus

7 analysts cover KPTI: 0 strong buy, 6 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $15.83.

Common questions about KPTI

Who owns KPTI stock?: Hedge funds tracked by Rallies that own KPTI include Davidson Kempner and Panagora Asset. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Karyopharm Therapeutics Inc..
Does Rallies show 13F holders for KPTI?: Yes. Rallies tracks hedge fund and 13F ownership data for KPTI, including fund names, share counts, latest tracked quarter, and position changes when available.
Is KPTI research on Rallies investment advice?: No. Rallies provides research, data, and educational context for KPTI. It does not provide personalized investment advice.